Expert Insights into Fabry Disease: A Case-Based Exploration for Effective Disease Management

Program Description

Fabry disease (FD) presents significant challenges in clinical practice, with nonspecific and
heterogeneous symptoms that frequently obscure early recognition and contribute to missed or delayed diagnoses. Despite expanded availability of enzyme, genetic, and biomarker testing, inconsistent application of these tools continues to impede timely identification. Even after diagnosis, clinicians must navigate nuanced decisions around individualized treatment, monitoring strategies, and the integration of newer therapeutic options to optimize long-term outcomes.

This case-based activity is designed to explore these complexities through expert-guided discussion using a SOAP-note framework (Subjective, Objective, Assessment, and
Plan). Through realistic clinical scenarios, faculty will walk learners through key considerations in recognizing diverse presentations, selecting and interpreting appropriate diagnostic evaluations, and tailoring treatment strategies based on phenotype, organ involvement, and disease trajectory. Ultimately, the program aims to help clinicians strengthen their diagnostic acumen, apply evidence-based management strategies, and deliver more timely, personalized care for individuals living with FD.

Target Audience

The target audience for this activity includes cardiologists, nephrologists, neurologists, medical geneticists, and primary care physicians as well as advanced practice professionals (e.g., NPs and PAs) and pharmacists working across these specialties.

Learning Objectives

Upon completion of this activity, the learner should be able to:

  • Evaluate and differentiate the diverse clinical symptoms of FD to improve diagnostic accuracy and reduce misdiagnosis
  • Employ evidence-based practice patterns for screening and diagnosis of FD to facilitate early detection
  • Optimize individualized treatment strategies for FD to enhance patient outcomes and quality of life
Course summary
Available credit: 
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
Course opens: 
12/29/2025
Course expires: 
12/29/2026
Cost:
$0.00
Rating: 
0
  Atul Mehta, BA, MB BChir, MRCP, MRCPath, MD
  Emeritus Professor in Hematology
  University College London School of Medicine
  London, England
  United Kingdom
 
 
  Eric Wallace, MD
  Professor of Medicine
  Division of Nephrology, Department of Medicine
  University of Alabama at Birmingham
  Birmingham, Alabama

This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.

    

Accreditation Statement

This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

PHYSICIAN CREDIT
Purdue University designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
PHARMACISTS
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Purdue will award a maximum of 0.75 contact hours (0.75 CEUs) to pharmacists who participate in this knowledge-based activity.
 
CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Participation will be given upon completion of the activity enabling participants to register their credit with the appropriate licensing boards or associations.
The American Association of Nurse Practitioners (NPs) accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME. For the purpose of recertification, the American Nurse Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits issued by providers accredited by the ACCME.

Conflicts of Interest Disclosure Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

All relevant conflicts of interest have been mitigated prior to the start of the activity.

None of the planners, reviewers, Efficient LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Faculty Disclosures

Professor Mehta reports no financial disclosures
 
Dr. Wallace reports the following financial relationships:
Consultant:  AceLink Therapeutics; Chiesi USA, Inc.; Inceptive; Kyowa Kirin Co., Ltd.; Sangamo Therapeutics; and Sanofi-Genzyme
Grants: Chiesi; Idorsia Pharmaceuticals Ltd; Sanofi-Genzyme; and uniQure
Speakers Bureau: Natera, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period 12/29/25, through 12/29/26, participants must: 1) review the learning objectives and faculty disclosures; 2) complete the pre-activity assessment; 3) watch the educational activity; 4) complete the posttest by recording the best answer to each question; and 5) complete the evaluation form.

Commercial Support

This activity is supported by educational grants from Amicus Therapeutics Inc. and Chiesi.

Available Credit

  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance

Price

Cost:
$0.00
Please login or register to take this course.